Skip to content
Company Analysis

Akebia Therapeutics, Inc. AKBA

A comprehensive view of key metrics, scores, and financial health for Akebia Therapeutics, Inc.

Overview of Akebia Therapeutics, Inc.

AKBA NCM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Micro Cap
Akebia Therapeutics, Inc. (AKBA), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $0.71, about 145.1% undervalued vs fair value, -64.8% 1Y return, ranked 443/1145 in sector.
Metrics Rev Growth 47.5% ROE 64.5% Gross Margin 83.3%
USD 0.71
0.14%
(Delayed)
• Vol 90d: 85.2%
52-Week Range
Market Cap
$196.30M
Enterprise Value
$90.32M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 88%
Confidence: 92%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.akebia.com
HQ Cambridge, MA
Employees 181
Fiscal year Dec 31

Next Events

Earnings Nov 5 Call: Nov 5

Fair Value Snapshot

Bear Base Bull
$2
$2
$2
Current: $0.71 +145% vs base

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$236.2M
47.5%%
Gross Profit
$196.7M
102.8%%
R&D Expense
$62.4M
65.6%%
Operating Income (EBIT)
$20.5M
139.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
332.3%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$1.3M

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Akebia Therapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
67
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • ROIC Sustainably Above Peers ROIC at 95.1th percentile exceeds peers and WACC, demonstrating superior capital allocation.
  • Scale Supporting Profitability Profitability at scale is strong (score 0.76), demonstrating competitive advantages.

Key risks

  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.35), suggesting weak customer stickiness.
  • Volatile Margins Suggest Cyclicality Margin volatility is high (stability score 0.39), suggesting cyclical exposure or competitive pressure.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
61
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 84% Coverage
Trade-Off Triangle Visualization A ternary plot showing AKBA's balance between Growth (32.2%), Profitability (36.2%), and Safety (31.6%). Growth 32% Safety 32% Profitability 36%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

64th percentile vs peers
65
Key Signals
Rev Growth YoY 47.5% 90p EPS Growth YoY 93.7% 74p Revenue CAGR 3Y -6.9% 25p
Strengths
  • Rev Growth YoY in top 20% of peers (47.5%, 90th percentile)
  • Superior capital returns - 2 return metrics above peer median
  • Growth above peer median with strong metric coverage (75%)
Risks

No significant risks identified for this axis.

Profitability

72th percentile vs peers
73
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

63th percentile vs peers
63
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Akebia Therapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$1.74
- - -
+145.1% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000